K
K. V. Zhdanov
Researcher at Kirov Military Medical Academy
Publications - 48
Citations - 167
K. V. Zhdanov is an academic researcher from Kirov Military Medical Academy. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 30 publications receiving 118 citations. Previous affiliations of K. V. Zhdanov include Military Academy & Military Medical Academy.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.
Lai Wei,Ji Dong Jia,Fu-Sheng Wang,Jun Qi Niu,Xu Min Zhao,Shengmei Mu,Li Wen Liang,Zaiqi Wang,Peggy Hwang,Michael N. Robertson,Paul Ingravallo,Ernest Asante-Appiah,Bo Wei,Barbara Evans,George J. Hanna,Rohit Talwani,Zhong Ping Duan,K. V. Zhdanov,Pin-Nan Cheng,Tawesak Tanwandee,Van Kinh Nguyen,Jeong Heo,Vasily Isakov,Jacob George +23 more
TL;DR: Evaluation of efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus infection from Asia–Pacific countries and Russia (C‐CORAL).
Journal ArticleDOI
Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.
Vasily Isakov,K. V. Zhdanov,Kathryn Kersey,Evguenia S. Svarovskaia,Benedetta Massetto,Yanni Zhu,Steven J. Knox,Igor G. Bakulin,Vladimir Chulanov +8 more
TL;DR: Sofosbuvir plus ribavirin was safe and well tolerated regardless of treatment duration, and the presence of the L159F resistance-associated variant at baseline was associated with a high SVR rate in patients with HCV genotype-3.
Journal ArticleDOI
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
Jacob George,Eduard Burnevich,I-Shyan Sheen,Jeong Heo,Nguyen Van Kinh,Tawesak Tanwandee,Pin-Nan Cheng,Do Young Kim,Won Young Tak,Svetlana Kizhlo,K. V. Zhdanov,Vasily Isakov,Liwen Liang,Pauline A. Lindore,Joy Ginanni,Bach-Yen Nguyen,Janice Wahl,Eliav Barr,Michael N. Robertson,Paul Ingravallo,Rohit Talwani,C‐Coral Study Investigators +21 more
TL;DR: EBR/GZR for 12 weeks provides an effective and well‐tolerated regimen for chronic HCV GT1 infection in treatment‐naive people from Asia‐Pacific countries and Russia, particularly for the large population with GT1b infection.
Journal ArticleDOI
Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19
Kristina V. Kasyanenko,K. V. Kozlov,Oleg V. Maltsev,Igor I. Lapikov,Vera V. Gordienko,Valerian V. Sharabhanov,Pavel V. Sorokin,K. V. Zhdanov +7 more
TL;DR: Yearly administration of riamilovir as opposed to the umifenovir and ribavirin in therapy of moderate SARS-CoV-2 infection was associated with significant shorter time to clinical improvement by 14 day of hospitalization.
Journal ArticleDOI
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden
Vasily Isakov,Vladimir Chulanov,D.T. Abdurakhmanov,Eduard Burnevich,Elena Nurmukhametova,Galina Kozhevnikova,Natalya Gankina,Sergey V. Zhuravel,Svetlana Romanova,Robert H. Hyland,Sophia Lu,Evguenia S. Svarovskaia,John McNally,Diana M. Brainard,Vladimir Ivashkin,Vyacheslav Morozov,Igor G. Bakulin,Martin Lagging,K. V. Zhdanov,Ola Weiland +19 more
TL;DR: Sofosbuvir/velpatasvir as a pangenotypic treatment for 12 weeks was highly effective in patients from Russia and Sweden infected with HCV genotypes 1, 2, or 3 and safe and well-tolerated.